Loading…
Changde-based drug maker, renamed under the CSPC group, selling branded heart, cancer, bone-joint and digestive injections and Chinese-medicine capsules.
Changde-based drug maker, renamed under the CSPC group, selling branded heart, cancer, bone-joint and digestive injections and Chinese-medicine capsules.
Sells branded prescription injections and Chinese-medicine capsules mainly to hospitals, using a mix of distributor recruitment and its own sales team, with several products held exclusive nationally. A court-led restructuring finished in early 2026, and the company now carries the CSPC group name in its title and logo.
Moat: narrow (regulatory licence, brand). Several nationally exclusive Chinese-medicine products on the national reimbursement list; now under the CSPC group name.
Headquarters: Changde, China · Employees: 463
Size CSPC Hunan Jingfeng Pharmaceutical (000908.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.13B, the 1192nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥5.37 on 6 Nov 2026.
Performance Over six months the shares fell 27.1%, against -12.0% for the median peer and -16.4% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 5.3% over the last twelve months (peer median -1.3%); the operating margin is -18.3% (peer median 9.7%).
Valuation It trades at 30.2× enterprise value to sales against a peer median of 3.4× (4th most expensive of 20).
Capital Return on invested capital runs 17.1 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥414M | CN¥375M | CN¥412M | CN¥650M | CN¥833M |
| Revenue growth | — | -9% | -37% | -22% | — |
| Gross profit | CN¥270M | CN¥215M | CN¥240M | CN¥421M | CN¥599M |
| EBITDA | n/a | -CN¥16.2M | CN¥11.1M | -CN¥56.9M | CN¥42.8M |
| Net income | -CN¥34.8M | -CN¥80.9M | CN¥152M | -CN¥236M | -CN¥123M |
| Free cash flow | -CN¥159M | CN¥54.8M | -CN¥6.93M | CN¥24.6M | CN¥110M |
| Capital expenditure | CN¥63.9M | CN¥4.57M | CN¥1.38M | CN¥10.4M | CN¥13.5M |
| Total debt | CN¥6.73M | CN¥286M | CN¥466M | CN¥601M | CN¥608M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | $2.13B | -27% | +5% | -18% | 30.2× | n/a |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 8.8× | 14.9% |
| Tasly Pharmaceutical 600535.SS | $3.20B | -5% | -4% | 19% | 2.3× | -7.6% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | $4.02B | -6% | +32% | 21% | 3.1× | -3.2% |
| Shandong Buchang Pharmaceuticals 603858.SS | $2.31B | -7% | +4% | 10% | 1.5× | -2.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000908.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.8% | -0.6% | 4th lowest of 21 |
| 6-month return | -27.1% | -12.0% | 7th lowest of 21 |
| Distance from 52-week high | -43.4% | -30.8% | 7th lowest of 21 |
| Revenue growth (TTM) | +5.3% | -1.3% | 6th highest of 20 |
| Operating margin | -18.3% | 9.7% | 4th lowest of 20 |
| EV / Sales | 30.2× | 3.4× | 4th most expensive of 20 |
| ROIC minus cost of capital | -17.1 pp | -1.7 pp | 3rd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $2.13B | -27% | +5% | -18% | 30.2× | n/a | n/a |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $2.12B | -41% | -18% | 9% | 15.5× | 37.9% | +0.9% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.12B | +17% | -1% | 14% | 2.5× | 2.4% | +15.7% |
| Dermapharm DMP.DE | Germany | $2.11B | -25% | 0% | 22% | 2.4× | -3.8% | +8.0% |
| Zymeworks ZYME | United States | $2.10B | +24% | -70% | -419% | 56.6× | n/a | n/a |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.15B | -3% | +9% | 14% | 3.4× | 6.1% | +6.4% |
| Harbin Pharmaceutical 600664.SS | China | $2.10B | +55% | +2% | 5% | 0.9× | -2.9% | +8.2% |
| Haw Par H02.SI | Singapore | $2.18B | -27% | -13% | 30% | 8.9× | 3.7% | +15.7% |
| Biohaven BHVN | United States | $2.19B | +47% | n/a | n/a | n/a | n/a | n/a |
| Perrigo PRGO | United States | $2.20B | +35% | -4% | 5% | 1.3× | 13.1% | +0.8% |
| Jinyu Bio-Technology 600201.SS | China | $2.04B | -15% | +22% | 10% | 7.7× | 24.4% | -2.4% |
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 3.6× | -0.2% | +2.9% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.02B | +7% | +5% | 22% | 3.2× | -4.8% | +10.6% |
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 2.2× | 11.9% | +5.0% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $2.01B | -27% | +7% | 13% | 1.6× | 1.2% | +14.1% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.01B | +24% | +20% | 12% | 2.4× | 25.0% | +6.5% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $2.01B | -9% | -9% | 30% | 5.2× | 9.1% | +9.3% |
| BrightGene Bio-Medical Technology 688166.SS | China | $2.00B | -51% | +14% | 7% | 11.1× | 38.5% | +9.2% |
| NewAmsterdam Pharma NAMS | United States | $2.26B | -51% | -26% | -900% | 62.8× | n/a | n/a |
| United Laboratories International 3933.HK | Hong Kong | $2.00B | -19% | -13% | 5% | 0.7× | 3.7% | +7.8% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.26B | -35% | 0% | -47% | 34.7× | n/a | n/a |